A recent British study, That a drug to treat prostate cancer, can save more lives and improve the chances of life, if taken in the early stages of the disease.
The study was carried out by researchers at the University of Birmingham and published in the New England Journal of Medicine.
The trials focused on the drug Abiraterone, which is used to treat prostate cancer, as an additional treatment for patients who were about to start a long-term hormone therapy.
Epitirone, also known as zeitiga, is a hormone therapy. Unlike chemotherapy, which kills cancer cells, it stops more testosterone from reaching the prostate gland to stifle tumor growth.
The trial included nearly 2,000 patients, half of whom were treated with hormones, while the other half received hormone therapy and abratiron. During the treatment, 184 deaths occurred in the group receiving hormone therapy and abterone, compared to 262 deaths in the hormone-treated group alone.
"This is the strongest result I've ever seen in a prostate cancer trial," said research leader Professor Nicholas James. "Deaths have been significantly reduced beyond any other experience."
"Epatirone is already used to treat some men who have spread the disease in their bodies and their results have shown that many men can benefit."
Prostate cancer, the second most common cancer among men after lung cancer, has infected more than 1 million people worldwide in 2012 alone, of which more than 307,000 have died of the disease, according to the World Health Organization.
loading...
Enregistrer un commentaire